By Bernell Simons
As South Africa receives its first shipment of a groundbreaking HIV prevention injection, health officials believe the country could be entering a decisive new phase in its decades-long battle against AIDS. The arrival of 37,920 doses of Lenacapavir — a long-acting jab administered just twice a year — signals more than a medical milestone; it represents a fundamental shift in how HIV prevention may be delivered in a country still carrying the world’s heaviest burden of the virus. For a fight long defined by daily pills, fragile adherence and overstretched clinics, this moment offers something rare: a simpler, more realistic approach to protection — and, potentially, a turning point in the effort to end new infections.
For decades, the battle against HIV has shaped South Africa’s public health story — fought in clinics, classrooms and communities against one of the most devastating epidemics of the modern era. Now, that fight may be changing shape. The Department of Health has confirmed that the shipment landed via OR Tambo International Airport last week, marking the first time Lenacapavir will be available in the country. For health authorities, this is more than a delivery. It is a shift. From daily burden to twice-yearly protection.
Unlike traditional HIV prevention methods that rely on daily tablets, Lenacapavir requires just one injection every six months — a difference experts say could be transformative. In a country where adherence remains one of the biggest barriers to effective prevention, reducing HIV protection to two clinic visits a year offers something the system has long struggled to achieve: consistency. “This is about expanding choice,” health officials say — particularly for people who face barriers to daily medication, including stigma, unstable living conditions or limited access to healthcare.
The drug is expected to play a key role in reaching populations most vulnerable to new infections, including adolescent girls and young women, sex workers, and men who have sex with men. A system under pressure — and the promise of innovation. The breakthrough arrives within a healthcare system still under strain. Overcrowded clinics, long queues and staff shortages remain a daily reality for many South Africans. That is where health officials say new approaches — not just new medicines — are critical. FreeProvincial spokesperson Mondli Mvambi points to the rollout of six-month multi-month dispensing (6MMD) as part of a broader strategy to ease pressure on facilities. “Patients who are stable and consistent can receive a six-month supply of their treatment,” he explained.
“That means fewer clinic visits, shorter queues, and more efficient use of resources.” The model is designed to reward adherence — and free up capacity for those who need care most. In that context, Lenacapavir forms part of a wider shift: moving HIV care and prevention away from rigid, facility-based systems toward more flexible, patient-centred approaches. “In the long term, this will assist us,” Mvambi said. “If we prevent new infections among at-risk populations, we reduce the burden on the entire system.”
The parallel battle: misinformation. Yet alongside medical progress, another battle continues — one not fought in laboratories, but in communities: misinformation. Health officials are increasingly concerned about voices — including some community and religious leaders — who discourage people from using scientifically tested medication. National Department of Health spokesperson Fos ter Mohale has issued a clear warning. “When a medicine has been scientifically proven to be safe and effective, why would you believe someone who tells you otherwise?” he said. He described such messaging as “dangerous and misleading,” particularly when it deters people from accessing life-saving prevention and treatment.
“Taking scientifically tested medication prevents disease and saves lives. That is the reality.” Not a vaccine — but a breakthrough.Officials stress that Lenacapavir is not a vaccine. It is a preventive medicine designed to stop HIV infection before it occurs — but in terms of impact, experts say it could be just as significant. Globally, it is being hailed as one of the most promising developments in HIV prevention in years, not only because of its effectiveness, but because of its practicality.
And in South Africa, practicality matters. The country still carries the largest HIV burden in the world, with an estimated eight million people living with HIV. While more than six million are receiving antiretroviral treatment, new infections continue — particularly among young women and vulnerable communities. The challenge has never been the absence of medicine. It has been debated whether people can realistically use it. Phased rollout, long-term ambition.
The Department of Health has confirmed that Lenacapavir will be introduced through a phased rollout, with priority given to high-incidence districts and vulnerable populations. An official national launch is expected in the coming weeks, led by President Cyril Ramaphosa in consultation with Health Minister Dr Aaron Motsoaledi. Government says the rollout aligns with the Global AIDS Strategy for 2026–2030, aimed at reducing new infections and sustaining long-term HIV prevention systems. But beyond strategy and timelines, the arrival of Lenacapavir carries symbolic weight. It signals a shift — from managing the epidemic to trying to end it. South Africa’s HIV response is already among the most extensive in the world.
AIDS-related deaths have dropped by more than 60% since 2010, while new infections have declined significantly. Lenacapavir does not begin that story. It builds on it. A continuation shaped not by crisis, but by progress — by science, adaptation and persistence. Still, no breakthrough exists in isolation. Medicines require trust. Systems require capacity. And prevention requires behaviour change. The arrival of 37,920 doses may seem small against the scale of the epidemic, but its significance lies elsewhere.
In what it represents. A shift toward simpler prevention. A move toward patient-centred care. And a renewed push to outpace a virus that has shaped generations. Because change does not always arrive in sweeping declarations or historic speeches. Sometimes it arrives quietly — in the form of a shipment, in the routine of a clinic, in a single injection.
And if this moment holds, Lenacapavir may one day be remembered not as just another medical advance, but as the point where the tide finally began to turn.
